The purpose of this paper is to provide the rationale for therapeutic silencing of the alpha-synuclein gene (SNCA) in Parkinson’s disease (PD). The paper reviews the public health significance of PD; the causal links between rare SNCA variants and familial PD; the association of common SNCA variants and PD susceptibility; the association of SNCA variants also with age at onset and motor and cognitive outcomes in PD; therapeutic strategies targeting SNCA in PD; and preliminary findings and considerations on small interfering RNA-based therapies and PD.

Citations

Citations to this article as recorded by  

• Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera
  Yuquan Tong, Peiyuan Zhang, Xueyi Yang, Xiaohui Liu, Jie Zhang, Magda Grudniewska, Ikrak Jung, Daniel Abegg, Jun Liu, Jessica L. Childs-Disney, Quentin M. R. Gibaut, Hafeez S. Haniff, Alexander Adibekian, M. Maral Mouradian, Matthew D. Disney
  Proceedings of the National Academy of Sciences.2024;[Epub]     CrossRef
• Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments
  Ankita Wal, Pranay Wal, Himangi Vig, Nem Kumar Jain, Shruti Rathore, Karthickeyan Krishnan, Ashish Srivastava
  Current Drug Discovery Technologies.2023;[Epub]     CrossRef
• Antisense therapies in neurological diseases
  Jean-Baptiste Brunet de Courssou, Alexandra Durr, David Adams, Jean-Christophe Corvol, Louise-Laure Mariani
  Brain.2022; 145(3): 816.     CrossRef
• Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
  L. Ma, M. Gholam Azad, M. Dharmasivam, V. Richardson, R.J. Quinn, Y. Feng, D.L. Pountney, K.F. Tonissen, G.D. Mellick, I. Yanatori, D.R. Richardson
  Redox Biology.2021; 41: 101896.     CrossRef
• Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA
  Peiyuan Zhang, Hye-Jin Park, Jie Zhang, Eunsung Junn, Ryan J. Andrews, Sai Pradeep Velagapudi, Daniel Abegg, Kamalakannan Vishnu, Matthew G. Costales, Jessica L. Childs-Disney, Alexander Adibekian, Walter N. Moss, M. Maral Mouradian, Matthew D. Disney
  Proceedings of the National Academy of Sciences.2020; 117(3): 1457.     CrossRef
• Small molecule recognition of disease-relevant RNA structures
  Samantha M. Meyer, Christopher C. Williams, Yoshihiro Akahori, Toru Tanaka, Haruo Aikawa, Yuquan Tong, Jessica L. Childs-Disney, Matthew D. Disney
  Chemical Society Reviews.2020; 49(19): 7167.     CrossRef
• Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease
  Yun Joong Kim, Junbeom Jeon, Jaemoon Shin, Nan Young Kim, Jeong Hoon Hong, Jae‐Min Oh, SangKyoon Hong, Yeo Jin Kim, Young‐Eun Kim, Suk Yun Kang, Hyeo‐Il Ma, Unjoo Lee, Jeehee Yoon
  Movement Disorders.2017; 32(8): 1211.     CrossRef
• Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy
  Michele Schlich, Francesca Longhena, Gaia Faustini, Caitriona M. O’Driscoll, Chiara Sinico, Anna Maria Fadda, Arianna Bellucci, Francesco Lai
  Nano Research.2017; 10(10): 3496.     CrossRef
• Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
  Elvira Valera, Brian Spencer, Eliezer Masliah
  Neurotherapeutics.2016; 13(1): 179.     CrossRef
• Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders
  Hayate Javed, Sindhu A Menon, Karima M Al-Mansoori, Abdelmojib Al-Wandi, Nour K Majbour, Mustafa T Ardah, Shiji Varghese, Nishant N Vaikath, M Emdadul Haque, Mimoun Azzouz, Omar MA El-Agnaf
  Molecular Therapy.2016; 24(4): 746.     CrossRef

During the last two decades, the many developments in the treatment of movement disorders such as Parkinson disease and dystonia have enhanced our understanding on organization of the basal ganglia, and this knowledge has led to other advances in the field. According to many electrophysiological and anatomical findings, it is considered that motor information from different cortical areas is processed through several cortico-basal ganglia loops principally in a parallel fashion and somatotopy from each cortical area is also well preserved in each loop. Moreover, recent studies suggest that not only the parallel processing but also some convergence of information occur through the basal ganglia. Information from cortical areas whose functions are close to each other tends to converge in the basal ganglia. The cortico-basal ganglia loops should be comprehended more as a network rather than as separated subdivisions. However, the functions of this convergence still remain unknown. It is important even for clinical doctors to be well informed about this kind of current knowledge because some symptoms of movement disorders may be explained by disorganization of the information network in the basal ganglia.

Citations

Citations to this article as recorded by  

• Parvalbumin+and Npas1+Pallidal Neurons Have Distinct Circuit Topology and Function
  Arin Pamukcu, Qiaoling Cui, Harry S. Xenias, Brianna L. Berceau, Elizabeth C. Augustine, Isabel Fan, Saivasudha Chalasani, Adam W. Hantman, Talia N. Lerner, Simina M. Boca, C. Savio Chan
  The Journal of Neuroscience.2020; 40(41): 7855.     CrossRef

Deep Brain Stimulation (DBS), arguably, is the most dramatic development in movement disorders since the levodopa for Parkinson’s disease. Yet, its mechanisms of action of DBS are unknown. However, DBS related research already has demonstrated that current concepts of basal ganglia pathophysiology are wrong. Specifically, the notion that over-activity of the globus pallidus interna causes parkinsonism, the basis for the most current theories, is no longer tenable. The development of any new theory will be aided by an understanding of how current theories are wrong and why have these flawed theories persist. Many of the problems of current theories are more matters of inference, assumptions, presumptions, and the accepted level of ambiguity than they are of fact. Consequently, it is imperative that these issues be addressed. Just as the inappropriate use of a tool or method is grounds for criticism, methods of reasoning are tools that can be used inappropriately and should be subject to discussion just as misuse of any other tool. Thorough criticism can provide very important lesions though the process could be mistaken as harsh or personal; neither is the case here. At the least, such analyzes can point to potential pitfalls that could be avoided in the development of new theories. As will be discussed, theories are important for the development of therapies but perhaps most important, for the acceptance of new therapies, as was the case for the recent resurgence of interest in surgical therapies.

Citations

Citations to this article as recorded by  

• Grid cells: the missing link in understanding Parkinson’s disease?
  Alexander Reinshagen
  Frontiers in Neuroscience.2024;[Epub]     CrossRef
• Basal ganglia and beyond: The interplay between motor and cognitive aspects in Parkinson’s disease rehabilitation
  Davide Ferrazzoli, Paola Ortelli, Graziella Madeo, Nir Giladi, Giselle M. Petzinger, Giuseppe Frazzitta
  Neuroscience & Biobehavioral Reviews.2018; 90: 294.     CrossRef
• Neuronal Entropy-Rate Feature of Entopeduncular Nucleus in Rat Model of Parkinson’s Disease
  Olivier Darbin, Xingxing Jin, Christof Von Wrangel, Kerstin Schwabe, Atsushi Nambu, Dean K. Naritoku, Joachim K. Krauss, Mesbah Alam
  International Journal of Neural Systems.2016; 26(02): 1550038.     CrossRef

Psychogenic movement disorders (PMD) are a group of disorders which are in the border zone between neurology and psychiatry. All necessary laboratory investigations should be done to rule out an underlying organic disorder. While clinical acumen of a trained movement disorder specialist may be sufficient to diagnose most PMD, there are clinical situations where electrophysiological tests are required either to rule out an organic movement disorder or even diagnose a PMD. Current electrophysiological test are most useful for tremor, followed by jerks and least for spasms or dystonia. Commonly used electrophysiologic tests include multichannel surface electromyography (EMG), accelerometry, electroencephalography time locked with EMG, premovement potential (Bereitschaftspotential), and somatosensory evoked potentials. Psychogenic tremor is a low frequency tremor with variable frequency and duration of EMG bursts, entrainable, has a high coherence with voluntary movements, and presence of coactivation sign. Patients with psychogenic jerks have well organized triphasic pattern of activation of agonist and antagonist muscles. The jerks are associated with EMG bursts of long duration (usually > 70 ms), long and variable latencies in stimulus induced jerks, absence of craniocaudal pattern of muscle recruitment in apparent startle response, and often a Breitschaftspotential (premovement potential) precedes the jerk. Electrophysiological characterization of psychogenic dystonia is difficult and the tests are usually performed to rule out organic dystonia with characteristic findings. Finally, caution should be exerted in interpreting the electrophysiological tests as both false positive and false negative diagnosis of PMD may still occur.

Citations

Citations to this article as recorded by  

• Investigation of Phase Shifts Using AUC Diagrams: Application to Differential Diagnosis of Parkinson’s Disease and Essential Tremor
  Olga S. Sushkova, Alexei A. Morozov, Ivan A. Kershner, Margarita N. Khokhlova, Alexandra V. Gabova, Alexei V. Karabanov, Larisa A. Chigaleichick, Sergei N. Illarioshkin
  Sensors.2023; 23(3): 1531.     CrossRef
• Electrophysiology in Functional Movement Disorders: An Update
  Nitish Kamble, Pramod Kumar Pal
  Tremor and Other Hyperkinetic Movements.2023;[Epub]     CrossRef
• Video electroencephalogram combined with electromyography in the diagnosis of hyperkinetic movement disorders with an unknown cause
  Jianhua Chen, Xiangqin Zhou, Qiang Lu, Liri Jin, Yan Huang
  Neurological Sciences.2021; 42(9): 3801.     CrossRef
• Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders
  Gerard Saranza, Daniel Vargas-Mendez, Anthony E. Lang, Robert Chen
  Clinical Neurophysiology Practice.2021; 6: 103.     CrossRef
• Principles of Electrophysiological Assessments for Movement Disorders
  Kai-Hsiang Stanley Chen, Robert Chen
  Journal of Movement Disorders.2020; 13(1): 27.     CrossRef
• A case of abdominal functional myoclonus analyzed by movement related cortical potentials
  Ryosuke Urabe, Masaya Kubota
  Brain and Development.2020; 42(9): 700.     CrossRef
• Focal localized enhanced physiological tremor after physical insult
  Sang-Won Yoo, Myungah Lee, Joong-Seok Kim, Kwang-Soo Lee
  Neurological Sciences.2019; 40(12): 2641.     CrossRef
• Sleep-Related Movement Disorders: Hypnic Jerks
  Robyn Whitney, Shelly K. Weiss
  Current Sleep Medicine Reports.2018; 4(1): 19.     CrossRef

Citations

Citations to this article as recorded by  

• Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation
  Khaled Radad, Rudolf Moldzio, Christopher Krewenka, Barbara Kranner, Wolf-Dieter Rausch
  Exploration of Neuroprotective Therapy.2023; : 24.     CrossRef
• Central retinal microvasculature damage is associated with orthostatic hypotension in Parkinson’s disease
  Jong Hyeon Ahn, Min Chae Kang, Dongyoung Lee, Jin Whan Cho, Kyung-Ah Park, Jinyoung Youn
  npj Parkinson's Disease.2023;[Epub]     CrossRef
• Pronounced Orthostatic Hypotension in GBA-Related Parkinson’s Disease
  Tatiana Usnich, Henrike Hanssen, Katja Lohmann, Christina Lohse, Christine Klein, Meike Kasten, Norbert Brüggemann
  Journal of Parkinson's Disease.2022; 12(5): 1539.     CrossRef
• Could Small Heat Shock Protein HSP27 Be a First-Line Target for Preventing Protein Aggregation in Parkinson’s Disease?
  Javier Navarro-Zaragoza, Lorena Cuenca-Bermejo, Pilar Almela, María-Luisa Laorden, María-Trinidad Herrero
  International Journal of Molecular Sciences.2021; 22(6): 3038.     CrossRef
• Delayed orthostatic hypotension in Parkinson’s disease
  Sang-Won Yoo, Joong-Seok Kim, Ji-Yeon Yoo, Eunkyeong Yun, Uicheul Yoon, Na-Young Shin, Kwang-Soo Lee
  npj Parkinson's Disease.2021;[Epub]     CrossRef
• Neurogenic orthostatic hypotension in early stage Parkinson's disease: New insights from the first 105 patients of the BoProPark study
  Francesca Baschieri, Luisa Sambati, Pietro Guaraldi, Giorgio Barletta, Pietro Cortelli, Giovanna Calandra-Buonaura
  Parkinsonism & Related Disorders.2021; 93: 12.     CrossRef
• Trajectory Analysis of Orthostatic Hypotension in Parkinson’s Disease: Results From Parkinson’s Progression Markers Initiative Cohort
  Kui Chen, Kangshuai Du, Yichen Zhao, Yongzhe Gu, Yanxin Zhao
  Frontiers in Aging Neuroscience.2021;[Epub]     CrossRef
• Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment
  Zhichun Chen, Guanglu Li, Jun Liu
  Neurobiology of Disease.2020; 134: 104700.     CrossRef
• Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease
  Cecilia Quarracino, Matilde Otero-Losada, Francisco Capani, Santiago Pérez-Lloret
  Clinical Autonomic Research.2020; 30(3): 265.     CrossRef
• Orthostatic hypotension in Parkinson disease
  Ylva Hivand Hiorth, Kenn Freddy Pedersen, Ingvild Dalen, Ole-Bjørn Tysnes, Guido Alves
  Neurology.2019;[Epub]     CrossRef
• The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review
  Panagiotis Zis, Roberto Erro, Courtney C Walton, Anna Sauerbier, Kallol Ray Chaudhuri
  npj Parkinson's Disease.2015;[Epub]     CrossRef
• Orthostatic Hypotension and Cognitive Impairment in <i>De Novo</i> Patients with Parkinson’s Disease
  Hyo-Jin Bae, Jun-Ho Lim, Sang-Myung Cheon
  Journal of Movement Disorders.2014; 7(2): 102.     CrossRef

Citations

Citations to this article as recorded by  

• Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology‐Proven Cases
  Luca Marsili, Kevin R. Duque, Nathan Gregor, Elhusseini Abdelghany, Jesus Abanto, Andrew P. Duker, Matthew C. Hagen, Alberto J. Espay, Matteo Bologna
  Movement Disorders.2023; 38(3): 496.     CrossRef
• The Sequence Effect Worsens Over Time in Parkinson’s Disease and Responds to Open and Closed-Loop Subthalamic Nucleus Deep Brain Stimulation
  Yasmine M. Kehnemouyi, Matthew N. Petrucci, Kevin B. Wilkins, Jillian A. Melbourne, Helen M. Bronte-Stewart
  Journal of Parkinson's Disease.2023; 13(4): 537.     CrossRef
• Neurofeedback-guided kinesthetic motor imagery training in Parkinson’s disease: Randomized trial
  Sule Tinaz, Serageldin Kamel, Sai S. Aravala, Mohamed Elfil, Ahmed Bayoumi, Amar Patel, Dustin Scheinost, Rajita Sinha, Michelle Hampson
  NeuroImage: Clinical.2022; 34: 102980.     CrossRef
• The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes
  Daniele Belvisi, Andrea Fabbrini, Maria Ilenia De Bartolo, Matteo Costanzo, Nicoletta Manzo, Giovanni Fabbrini, Giovanni Defazio, Antonella Conte, Alfredo Berardelli
  Movement Disorders.2021; 36(2): 370.     CrossRef
• The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait
  Alessia Putortì, Michele Corrado, Micol Avenali, Daniele Martinelli, Marta Allena, Silvano Cristina, Valentina Grillo, Luca Martinis, Stefano Tamburin, Mariano Serrao, Antonio Pisani, Cristina Tassorelli, Roberto De Icco
  Frontiers in Neurology.2021;[Epub]     CrossRef
• Evolving concepts on bradykinesia
  Matteo Bologna, Giulia Paparella, Alfonso Fasano, Mark Hallett, Alfredo Berardelli
  Brain.2020; 143(3): 727.     CrossRef
• Effectiveness of Exercise on the Sequence Effect in Parkinson’s Disease
  Suk Yun Kang, Young Ho Sohn
  Journal of Movement Disorders.2020; 13(3): 213.     CrossRef
• Neurophysiological correlates of bradykinesia in Parkinson’s disease
  Matteo Bologna, Andrea Guerra, Giulia Paparella, Laura Giordo, Danilo Alunni Fegatelli, Anna Rita Vestri, John C Rothwell, Alfredo Berardelli
  Brain.2018; 141(8): 2432.     CrossRef
• Insula as the Interface Between Body Awareness and Movement: A Neurofeedback-Guided Kinesthetic Motor Imagery Study in Parkinson’s Disease
  Sule Tinaz, Kiran Para, Ana Vives-Rodriguez, Valeria Martinez-Kaigi, Keerthana Nalamada, Mine Sezgin, Dustin Scheinost, Michelle Hampson, Elan D. Louis, R. Todd Constable
  Frontiers in Human Neuroscience.2018;[Epub]     CrossRef
• Sequence Effect in Parkinson’s Disease Is Related to Motor Energetic Cost
  Sule Tinaz, Ajay S. Pillai, Mark Hallett
  Frontiers in Neurology.2016;[Epub]     CrossRef
• Bradykinesia in early and advanced Parkinson's disease
  Matteo Bologna, Giorgio Leodori, Paola Stirpe, Giulia Paparella, Donato Colella, Daniele Belvisi, Alfonso Fasano, Giovanni Fabbrini, Alfredo Berardelli
  Journal of the Neurological Sciences.2016; 369: 286.     CrossRef
• Neural correlates of progressive reduction of bradykinesia in de novo Parkinson's disease
  Eeksung Lee, Ji Eun Lee, Kwangsun Yoo, Jin Yong Hong, Jungsu Oh, Mun Kyung Sunwoo, Jae Seung Kim, Yong Jeong, Phil Hyu Lee, Young Ho Sohn, Suk Yun Kang
  Parkinsonism & Related Disorders.2014;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis
  Simona Raimo, Mariachiara Gaita, Maria Cropano, Giusi Mautone, Alfonsina D’Iorio, Luigi Trojano, Gabriella Santangelo
  Neuropsychology Review.2023; 33(2): 514.     CrossRef
• Morphological differences between the two major subtypes of multiple system atrophy with cognitive impairment
  Kurt A. Jellinger
  Parkinsonism & Related Disorders.2023; 107: 105273.     CrossRef
• Mild cognitive impairment in multiple system atrophy: a brain network disorder
  Kurt A. Jellinger
  Journal of Neural Transmission.2023; 130(10): 1231.     CrossRef
• Cognition in Patients With Multiple System Atrophy (MSA) and Its Neuroimaging Correlation: A Prospective Case-Control Study
  Santosh Dash, Rohan Mahale, M. Netravathi, Nitish L Kamble, Vikram Holla, Ravi Yadav, Pramod K Pal
  Cureus.2022;[Epub]     CrossRef
• Cognition in multiple system atrophy: a single‐center cohort study
  Sabine Eschlböck, Margarete Delazer, Florian Krismer, Thomas Bodner, Alessandra Fanciulli, Beatrice Heim, Antonio Heras Garvin, Christine Kaindlstorfer, Elfriede Karner, Katherina Mair, Christoph Rabensteiner, Cecilia Raccagni, Klaus Seppi, Werner Poewe,
  Annals of Clinical and Translational Neurology.2020; 7(2): 219.     CrossRef
• Neuropathological findings in multiple system atrophy with cognitive impairment
  Kurt A. Jellinger
  Journal of Neural Transmission.2020; 127(7): 1031.     CrossRef
• An update on MSA: premotor and non-motor features open a window of opportunities for early diagnosis and intervention
  Viorica Chelban, Daniela Catereniuc, Daniela Aftene, Alexandru Gasnas, Ekawat Vichayanrat, Valeria Iodice, Stanislav Groppa, Henry Houlden
  Journal of Neurology.2020; 267(9): 2754.     CrossRef
• A case of multiple system atrophy
  Jing Guo, Fuying Liu, Tingting Liu, Xin Zhang, Yong Luo
  Journal of International Medical Research.2019; 47(11): 5839.     CrossRef
• Cognitive impairment before changes appear on [18F]‐fluoro‐D‐glucose positron emission tomography images in a patient with possible early‐stage cerebellar‐predominant multiple system atrophy
  Masahiko Takaya, Masahiko Atsumi, Tomoyuki Hirose, Kazunari Ishii, Osamu Shirakawa
  Psychogeriatrics.2016; 16(3): 216.     CrossRef
• Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders
  Erin E. Robertson, Deborah A. Hall, Andrew R. McAsey, Joan A. O’Keefe
  The Clinical Neuropsychologist.2016; 30(6): 849.     CrossRef
• A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy
  Brian Spencer, Elvira Valera, Edward Rockenstein, Margarita Trejo-Morales, Anthony Adame, Eliezer Masliah
  Molecular Neurodegeneration.2015;[Epub]     CrossRef
• Cognitive Impairment and Its Structural Correlates in the Parkinsonian Subtype of Multiple System Atrophy
  Ji Sun Kim, Jin-ju Yang, Dong-Kyun Lee, Jong-min Lee, Jinyoung Youn, Jin Whan Cho
  Neurodegenerative Diseases.2015; 15(5): 294.     CrossRef

Various neurologic manifestations of herpes simplex virus (HSV) encephalitis have been reported on the literatures. Chorea, ballism, choreoathetosis and myoclonus were reported as movement disorders which might be related with brain lesion by HSV encephalitis, but negative myoclonus (NM) has never been reported before. NM can be characterized as a shock-like involuntary jerky movement caused by a sudden, brief interruption of muscle activity. We experienced a case of HSV encephalitis with NM in unilateral arm and leg. In polygraphic monitoring, electroencephalography (EMG) silent periods are 50–250 ms in duration with no detectable EMG correlate.

Citations

Citations to this article as recorded by  

• Epileptic negative myoclonus in herpes simplex virus encephalitis
  Neel Fotedar, James Dolbow, Madhura Layfield, Suraj Thyagaraj, Jonathan Zande
  Epileptic Disorders.2022; 24(2): 417.     CrossRef
• Myoclonus in the critically ill: Diagnosis, management, and clinical impact
  Raoul Sutter, Anette Ristic, Stephan Rüegg, Peter Fuhr
  Clinical Neurophysiology.2016; 127(1): 67.     CrossRef
• Chorée aiguë après encéphalite herpétique : réplication virale ou mécanisme immunologique ?
  H. Benrhouma, A. Nasri, I. Kraoua, H. Klaa, I. Turki, N. Gouider-Khouja
  Archives de Pédiatrie.2015; 22(9): 961.     CrossRef

Zolpidem is usually used for the treatment of insomnia as a hypnotic drug. It was also suggested to be effective in the treatment of dystonia in some studies. A 74-year-old woman had been suffering from frequent and intense bilateral spasms of the eyelids for 20 years. She has been treated with botulinum toxin injection and taken some medications. But, she experienced a little effect and was not satisfied with those treatments. Her symptom was improved after taking Zolpidem which had been prescribed for insomnia by her primary physician. She did not show any improvement after placebo injection and neostigmine test. This is the first report which shows improvement of isolated blepharospasm by Zolpidem in Korea. Zolpidem can be one of useful alternative pharmacological treatments for blepharospasm. Further randomized, blinded, placebo-controlled studies are needed to validate this finding.

Citations

Citations to this article as recorded by  

• Zolpidem for the Treatment of Dystonia
  Stephanie Patricia J. Badillo, Roland Dominic G. Jamora
  Frontiers in Neurology.2019;[Epub]     CrossRef
• Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease
  Antonio Daniele, Francesco Panza, Antonio Greco, Giancarlo Logroscino, Davide Seripa
  Parkinson's Disease.2016; 2016: 1.     CrossRef
• Medical treatment of dystonia
  Pichet Termsarasab, Thananan Thammongkolchai, Steven J. Frucht
  Journal of Clinical Movement Disorders.2016;[Epub]     CrossRef